Want to see IN:JUBLPHARMA full AI Analyst Report?
JUBLPHARMA Stock Chart & Stats
₹1056.10
₹15.25(1.49%)
At close: 4:00 PM EST
₹1056.10
₹15.25(1.49%)
Day’s Range― - ―
52-Week Range₹783.75 - ₹1,250.00
Previous CloseN/A
Volume282.20K
Average Volume (3M)7.42K
Market Cap
₹154.30B
Enterprise Value₹180.91B
Total Cash (Recent Filing)₹12.68B
Total Debt (Recent Filing)₹36.15B
Price to Earnings (P/E)38.7
Beta1.00
Next Earnings
Jul 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)25.16
Shares Outstanding159,281,140
10 Day Avg. Volume4,911
30 Day Avg. Volume7,424
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)1.82
Price to Sales (P/S)1.56
P/FCF Ratio-29.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)43.2
Revenue Forecast (FY)₹94.89B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelJubilant's mix across specialty finished drugs, CDMO, APIs and radiopharma provides multiple, structurally different revenue streams. This diversification reduces dependency on any single market cycle, supports cross-segment utilisation of manufacturing assets and underpins steady demand over medium term.
Consistent Revenue GrowthA sustained top-line expansion, including acceleration in FY2026, indicates durable end-market demand and commercial traction across products and contract services. Reliable revenue expansion improves the firm's ability to fund reinvestment, secure long-term contracts and support capacity planning.
Positive Operating Cash FlowConsistent positive operating cash flow shows core operations generate cash to run and reinvest the business. This operational cash coverage supports working-capital needs, contract fulfilment and incremental capex funding, preserving operational continuity across typical 2-6 month horizons.
Bears Say
Erratic Free Cash FlowHighly variable free cash flow undermines the company's ability to consistently deleverage, invest in growth or return capital. Recurrent negative FCF in recent years implies working-capital swings or high reinvestment needs, increasing financing risk and limiting strategic optionality over the medium term.
Volatile ProfitabilityWide swings in margins and a sharp gross-margin decline indicate unstable earnings quality and susceptibility to input costs, mix shifts or pricing pressure. This volatility complicates forecasting, capital allocation and long-term return expectations for investors and management alike.
Rising LeverageAn upward trend in debt increases fixed obligations and reduces financial flexibility. Even with a serviceable balance sheet, rising leverage elevates refinancing and interest-rate risk, constrains acquisitive or capex-backed growth options and weakens the credit profile over a multi-month horizon.
Jubilant Pharmova Limited News
JUBLPHARMA FAQ
What was Jubilant Pharmova Limited’s price range in the past 12 months?
Jubilant Pharmova Limited lowest stock price was ₹783.75 and its highest was ₹1250.00 in the past 12 months.
What is Jubilant Pharmova Limited’s market cap?
Jubilant Pharmova Limited’s market cap is ₹154.30B.
When is Jubilant Pharmova Limited’s upcoming earnings report date?
Jubilant Pharmova Limited’s upcoming earnings report date is Jul 17, 2026 which is in 11 days.
How were Jubilant Pharmova Limited’s earnings last quarter?
Jubilant Pharmova Limited released its earnings results on May 22, 2026. The company reported ₹7.8 earnings per share for the quarter, beating the consensus estimate of ₹7.45 by ₹0.35.
Is Jubilant Pharmova Limited overvalued?
According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Overvalued.
Does Jubilant Pharmova Limited pay dividends?
Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Jubilant Pharmova Limited dividends here
What is Jubilant Pharmova Limited’s EPS estimate?
Jubilant Pharmova Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jubilant Pharmova Limited have?
Jubilant Pharmova Limited has 159,281,140 shares outstanding.
What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?
Jubilant Pharmova Limited reported an EPS of ₹7.8 in its last earnings report, beating expectations of ₹7.45. Following the earnings report the stock price went down -0.544%.
Which hedge fund is a major shareholder of Jubilant Pharmova Limited?
Currently, no hedge funds are holding shares in IN:JUBLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jubilant Pharmova Limited
Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment is involved in a range of activities, including the production and distribution of allergy treatments, outsourced manufacturing of both sterile injectable and non-sterile medications, the creation of active pharmaceutical ingredients (APIs), and solid dose formulations. This division also markets radiopharmaceuticals through a network of 48 specialized pharmacies located across the United States. Its Contract Research & Development Services arm offers collaborative scientific investigation to pioneering pharmaceutical companies. Furthermore, the Proprietary Novel Drugs segment focuses on developing innovative therapies for conditions such as cancer and autoimmune diseases. Established in 1978 and headquartered in Noida, India, the company was formerly named Jubilant Life Sciences Limited before adopting its current designation, Jubilant Pharmova Limited, in February 2021.
Technical Analysis
Glenmark Life Sciences Limited
―
Granules India Limited
―
Neuland Laboratories Ltd.
―
Strides Pharma Science Ltd
―
Wockhardt Limited
―